mAbs delivered via subcutaneous (SC) injection provide numerous patient benefits and are currently the most common route of self-administered drugs. Yet these therapies must be formulated at high concentration, which may cause increased injection-site pain.
This article will discuss the use of citrate in SC formulations as compared to other buffers, as well as a formulation and excipients selection strategy that can be used to mitigate the risk of injection-site pain due to buffer, pH, and viscosity.
This content is sponsored by:
